• In July 2026, Paragon Advanced Labs announced a memorandum of understanding with McEwen Inc. to develop advanced laboratory services, including PhotonAssay, for the Gold Bar Mine Complex in Nevada, with potential future facilities at the Fox Complex in Ontario and El Gallo Mine in Mexico.
• An interesting aspect of this agreement is that McEwen will fund land and building construction while receiving a royalty on Paragon’s third-party lab revenues instead of rent, potentially creating a new income stream alongside improved on-site analytical capabilities.
• We’ll now examine how this PhotonAssay-focused lab partnership, and its potential expansion to other McEwen sites, may influence the company’s broader investment narrative.

The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

McEwen Investment Narrative Recap

To own McEwen, you need to believe the company can translate its multi-asset pipeline into consistent, profitable production while managing permitting, cost and financing pressures. The Paragon PhotonAssay partnership looks incremental rather than transformational in the short term, but it may modestly support operational reliability at Gold Bar. The bigger near term swing factor remains execution on core mines and development projects; persistent operational underperformance or project delays would still be the key risk.

Among recent announcements, the Grey Fox pre-feasibility study released in June 2026 stands out alongside the Paragon agreement. Grey Fox sits at the heart of McEwen’s Ontario growth plans, and its study frames one of the clearest potential sources of future production. If the PhotonAssay model is eventually extended to the Fox Complex, it could support tighter grade control and faster decision making there, indirectly affecting how investors view Grey Fox as a catalyst.

Yet alongside these promising developments, one risk in particular is something investors should be aware of...

McEwen's narrative projects $631.8 million revenue and $350.0 million earnings by 2029. This requires 38.9% yearly revenue growth and about a $276 million earnings increase from $74.1 million today.

Uncover how McEwen's forecasts yield a $32.10 fair value, a 86% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming McEwen could lift revenue to about US$577.2 million and earnings to roughly US$126.7 million by 2029, which is far more ambitious than the baseline view. When you set that against the PhotonAssay lab plan and the dependence on projects like Grey Fox coming online on schedule, you can see how opinions on McEwen’s future can differ widely and may shift again as this new agreement plays out.

Explore 7 other fair value estimates on McEwen - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your McEwen research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free McEwen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McEwen's overall financial health at a glance.

No Opportunity In McEwen?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.